Published in Clin Kidney J on January 06, 2016
Safety of intravenous iron use in chronic kidney disease. Curr Opin Nephrol Hypertens (2016) 0.96
Safety of intravenous iron in hemodialysis patients. Hemodial Int (2017) 0.75
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J (1984) 13.20
Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood (2002) 7.58
Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int (2014) 3.33
Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int (2014) 3.04
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant (2014) 2.91
The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc (2014) 2.88
Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA (2010) 2.71
Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol (2007) 2.62
Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol (2005) 2.49
KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis (2013) 2.43
Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products. JAMA (2015) 2.35
On the relative safety of parenteral iron formulations. Nephrol Dial Transplant (2004) 2.26
Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol (2004) 2.21
Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis (2010) 2.14
Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol (2013) 2.06
Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol (2010) 1.90
Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis (2001) 1.85
Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int (2004) 1.78
Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta (2011) 1.72
Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med (2012) 1.61
Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation (2002) 1.58
Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol (2009) 1.55
The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS One (2014) 1.54
Intravenous iron dextran in clinical medicine. JAMA (1980) 1.52
Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol (2004) 1.51
Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD. J Am Soc Nephrol (2014) 1.50
Do hemochromatosis mutations protect against iron-mediated atherogenesis? Circ Cardiovasc Genet (2009) 1.47
Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant (2005) 1.44
Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis (2010) 1.43
Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques. J Am Coll Cardiol (2011) 1.39
Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant (2013) 1.28
Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol (2002) 1.23
The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle. Am J Kidney Dis (2013) 1.12
Anaphylactoid reactions to Dextran 40 and 70: reports to the United States Food and Drug Administration, 1969 to 2004. J Vasc Surg (2006) 1.09
Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica (2014) 1.09
Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail (2007) 1.09
Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol (2012) 1.04
High-molecular weight iron dextran: a wolf in sheep's clothing? J Am Soc Nephrol (2008) 1.03
Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Acta Haematol (2009) 0.99
Non-transferrin-bound iron is associated with enhanced Staphylococcus aureus growth in hemodialysis patients receiving intravenous iron sucrose. Am J Nephrol (2006) 0.98
Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant (2014) 0.98
Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy (1994) 0.96
Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis (2004) 0.96
Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS One (2013) 0.96
Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol (2002) 0.96
Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol (2006) 0.96
Non-invasive assessment of tissue iron overload. Hematology Am Soc Hematol Educ Program (2009) 0.95
Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet (1982) 0.95
Hypersensitivity from intravenous iron products. Immunol Allergy Clin North Am (2014) 0.95
Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis (2013) 0.95
Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant (2012) 0.93
Iron sucrose impairs phagocytic function and promotes apoptosis in polymorphonuclear leukocytes. Am J Nephrol (2012) 0.91
Hepcidin destabilizes atherosclerotic plaque via overactivating macrophages after erythrophagocytosis. Arterioscler Thromb Vasc Biol (2012) 0.91
Understanding the Recent Increase in Ferritin Levels in United States Dialysis Patients: Potential Impact of Changes in Intravenous Iron and Erythropoiesis-Stimulating Agent Dosing. Clin J Am Soc Nephrol (2015) 0.89
Intravenous iron exposure and mortality in patients on hemodialysis. Clin J Am Soc Nephrol (2014) 0.89
Iron and infection in hemodialysis patients. Semin Dial (2013) 0.88
Association of markers of iron stores with outcomes in patients with nondialysis-dependent chronic kidney disease. Clin J Am Soc Nephrol (2008) 0.87
Lipid peroxidation products formation with various intravenous iron preparations in chronic kidney disease. Ren Fail (2009) 0.86
Testing the iron hypothesis in a mouse model of atherosclerosis. Cell Rep (2013) 0.85
Reassessment of Iron Biomarkers for Prediction of Dialysis Iron Overload: An MRI Study. PLoS One (2015) 0.84
Effect of intravenous iron on haemodialysis catheter microbial colonization and blood-borne infection. Nephrology (Carlton) (2005) 0.83
Concentrations of iron correlate with the extent of protein, but not lipid, oxidation in advanced human atherosclerotic lesions. Free Radic Biol Med (2006) 0.82
Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis. Am J Nephrol (2014) 0.82
Serum ferritin and tissue iron in anemic dialysis patients. Miner Electrolyte Metab (1997) 0.82
At pharmacologically relevant concentrations intravenous iron preparations cause pancreatic beta cell death. Am J Transl Res (2013) 0.81
Iron indices and survival in maintenance hemodialysis patients with and without polycystic kidney disease. Nephrol Dial Transplant (2013) 0.80
Does iron inhibit calcification during atherosclerosis? Free Radic Biol Med (2012) 0.80
Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013. Nephrol Dial Transplant (2015) 0.79
Oxidative effect of several intravenous iron complexes in the rat. Biometals (2013) 0.78
Effect of deferoxamine therapy on insulin resistance in end-stage renal disease patients with iron overload. Saudi J Kidney Dis Transpl (2014) 0.76
Cardiovascular outcomes of intravenous iron in perspective of clinical trials and the use of different iron preparations. Int J Cardiol (2015) 0.76
Impact of European medicines agency recommendations for hypersensitivity reactions on intravenous iron prescription in haemodialysis centres of the Lombardy region. J Nephrol (2015) 0.76
Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia. Hematology (2015) 0.76
Hepatic iron in hemodialysis patients. Kidney Int (2004) 0.76
Pure red cell aplasia induced by epoetin zeta. Clin Kidney J (2016) 0.75